Drug intelligence / Profile preview

Simparica Trio

Development stage
Unknown
Lead developer
Zoetis
Modality
Small Molecules
Administration
Oral
01

Overview

Simparica Trio is a veterinary combination drug formulated as a monthly chewable tablet for dogs. It contains three active ingredients—sarolaner, moxidectin, and pyrantel (as embonate)—and provides broad-spectrum protection against multiple parasites. The product is indicated for the prevention of heartworm disease caused by Dirofilaria immitis, treatment and control of roundworm (Toxocara canis, Toxascaris leonina), hookworm (Ancylostoma caninum, Uncinaria stenocephala), flea infestations (Ctenocephalides felis), and tick infestations including lone star tick (Amblyomma americanum), Gulf Coast tick (Amblyomma maculatum), American dog tick (Dermacentor variabilis), black-legged tick (Ixodes scapularis), and brown dog tick (Rhipicephalus sanguineus). - Sarolaner is an acaricide/insecticide from the isoxazoline class that inhibits GABA- and glutamate-gated chloride channels in arthropods, causing neuromuscular hyperexcitation and death. - Moxidectin is a macrocyclic lactone endectocide that interferes with chloride channel-mediated neurotransmission in nematodes leading to paralysis and death. - Pyrantel pamoate is a tetrahydropyrimidine-class anthelmintic acting as a depolarizing neuromuscular-blocking agent in susceptible nematodes resulting in paralysis or expulsion[1][3][5][8].

Brand names
Simparica Trio
Other names
sarolaner + moxidectin + pyrantelsarolaner + moxidectin + pyrantel pamoate
02

Targets

RDL (Insect GABA-gated chloride channel)Nicotinic Acetylcholine ReceptorGluCl (Glutamate-gated chloride channel)GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on Simparica Trio.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simparica Trio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call